Daniel Persky, MD

Associate Professor of Medicine

Fax: 
(520)-626-2225
Short Bio: 

Dr. Persky serves as an Associate Professor of Medicine at the University of Arizona College of Medicine.  He specializes in Hematology/Oncology, particularly in lymphoid malignancies, such as lymphoma, CLL, and others.

Dr. Persky received his Bachelor's Degree from Harvard University and his medical degree from the Albert Einstein College of Medicine in New York.  He completed his internship and residency at the Mayo Graduate School of Medicine in Rochester, Minnesota, then returned to New York to complete a three-year fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center.

Dr. Persky is board certified by the American Board of Internal Medicine, subspeciality of Medical Oncology.

Clinical Information
Specialty: 
Medical Oncologist
Clinical Focus: 

Lymphoid Malignancies

Clinical Practice Sites: 
The University of Arizona Cancer Center - North Campus
Research Information
Research Program: 
1. Therapeutic Development
Member Status: 
Associate Member
Summary of Research Activity: 

Clinical trials and clinical-laboratory collaborations in studying lymphoid malignancies. 

Selected Publications: 

1.    Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Ansell SM, Micallef IN, Markovic SN. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004 Feb;33(3):291-8. PMID: 14676784.

2.    Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, and Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. J Clin Oncol 2008 May 10;26(14):2258-63.  Epub 2008 Apr 14. PMID: 18413640.

3.    Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008 Oct 15;112(8):3425-33. Epub 2008 Jun 10. PMID: 18544678.

4.    Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma 2009 May;50(5):728-35. Epub 2009 Apr 15. PMID: 19373598; PMCID: PMC3532923.

5.    Persky DO, Moskowitz, CH, Filatov A, Saxena R, Haiyan C, Teruya-Feldstein. J. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin’s lymphoma. Appl Immunohistochem Mol Morphol 2010 Jan;18(1):35-40. PMID: 19701081.

6.    Schaffel R, Hedvat CV, Teruya-Feldstein J, Persky D, Maragulia J, Lin D, Portlock CS, Moskowitz CH, Zelenetz AD. Prognostic impact of proliferative index determined by quantitative image analysis and the mantle cell lymphoma International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol, 2010 Jan;21(1):133-9.PMID: 20019090; PMCID: PMC2795614.

7.    Stasik C, Nitta H, Zhang W,  Mosher C, Cook J, Tubbs R, Unger J, Brooks T,Persky DO, Wilkinson S,  Grogan T, Rimsza L. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica, 2010 April; 95(4): 597-603. PMID: 20378577; PMCID: PMC2857189.

8.    Koreishi AF, Saenz AJ, Persky DO, Cui H, Moskowitz A, Moskowitz CH, Teruya-Feldstein J. The role of cytotoxic and regulatory t cells in relapsed/refractory Hodgkin lymphoma. Appl Immunohistochem Mol Morphol, 2010 May;18(3):206-11. PMID: 20065852; PMCID: PMC3260943.

9.    Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Persky DO, Miller TP, Mahadevan D. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol. 2011 Apr 1;81(7):881-90. Epub 2011 Feb 1. PMID: 21291867; PMCID: PMC3792566.

10.  Qi W. Liu X, Cooke LS, Persky DO, Miller TP, Squires M, Mahadevan D.  AT9283, a novel aurora kinase inhibitor suppresses tumor growth in aggressive B-cell lymphomas.  Int J Cancer 2011 Jul 27. doi: 10.1002/ijc.26324 [Epub ahead of print]  PMID: 21796626.

11.  Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, LeBlanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012 Jun;97(6):937-42. Epub 2012 Jan 22.  PMID 22271896; PMCID 3366663.

Comment in: “Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?” Reply to "Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone". Haematologica. 2012;97(6):937-942. PMID 23125245; PMCID: PMC3487428.

12.  Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, Leblanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer. 2013 Jan 15;119(2):371-9. Epub 2012 Jul 25. PMID 22833464; PMCID: PMC3485430.

13.  Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res. 2013 Apr;37(4):434-9. Epub 2012 Nov 12. PMID 23153524; PMCID: PMC3816641.

14.  Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP. Histone deacetylase inhibitors activate CIITA and major histocompatibility complex class II antigen expression in diffuse large B cell lymphoma. Immunology. 2013 Jun 21. PMID: 23789844; PMCID: PMC3784172.

15.  Friedberg JW, Mahadevan D,  Jung J, Cebula E, Persky D, Lossos I, Agarwal AG, Zhou X, Leonard EJ, Bernstein SH. Phase 2 study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphoma. J Clin Oncol. 2014 Jan 1;32(1):44-50. PMID: 24043741; PMCID: PMC3867644.

Bio sketch: 
Professional Information
Board Certifications: 

Board Certified by the American Board of Internal Medicine, subspecialty of Medical Oncology

Professional Affiliations: 

American Society of Clinical Oncology

American Society of Hematology

SWOG (Southwest Oncology Group)

Honors: 

1992-1996               Harvard College Scholarship

1994, 1995              Ford Research Grant

1997                        National Cancer Institute Research Fellowship

2002                        Poster Finalist, ACP Minnesota and National Associates

Research Competition

2004, 2005              Mortimer J. Lacher Fellowship Award

2005                       ASH Clinical Research Training Institute

2005                       ASH Travel Award

2007                       SWOG Young Investigator Training Award

2010                       SWOG Coltman Fellowship Award

2012                       NIH Loan Repayment Program      

2013                       Best Doctors® 2013

Academic Information
Fellowship: 
Memorial Sloan-Kettering Cancer Center
Residency: 
Mayo Graduate School of Medicine, Rochester, MN
Medical School: 
Albert Einstein College of Medicine, NY
Undergraduate School: 
Harvard University